- Everest Medicines Announces European Commission Grants Approval of Kinpeygo® for Adults with Primary IgA Nephropathy to our Partner Calliditas Therapeutics
- Everest Medicines Announces Approval of Trodelvy® in China for Second-Line Metastatic Triple-Negative Breast Cancer
- Everest Medicines' Licensing Partner Gilead Sciences Announces Positive Results from Phase 3 TROPiCS-02 Study of Trodelvy® in Heavily Pre-treated HR+/HER2- Metastatic Breast Cancer Patients
- Everest Medicines' Licensing Partner Pfizer Presents ELEVATE Pivotal Findings Demonstrating Etrasimod's Potentially Best-in-Class Profile in Ulcerative Colitis
Everest Medicines Ltd (1952:HKG) closed at 16.72, 20.63% above the 52 week low of 13.86 set on Mar 15, 2022.
13.86Mar 15 202266.50Sep 14 2021
Markit short selling activity
|Market cap||4.88bn HKD|
|EPS (TTM)||-4.00 |
Data delayed at least 15 minutes, as of Aug 08 2022 09:08 BST.